Business
agilon health partners with primary-care physician groups to build Medicare-centric, globally capitated local care models for senior patients.
agilon's revenue slipped 2.1%, but medical economics worsened and the net loss expanded to $391.3M.
The read at a glance✓ Audited against SEC data
- Business mix — Medicare-focused primary-care platformNote
- Revenue — Revenue fell 2.1% to $5.93BWatch
- Profitability — Net loss widened to $391.3MWatch
- Cash burn — Free cash flow was -$119.0MWatch
- Balance sheet — Equity fell 73.1% to $126.7MWatch
- Insiders — 5 buys / 0 sells; $352K boughtOK
- Accounting — Altman-Z greyWatch
Where the revenue comes from
Fiscal 2025, as agilon health, inc. reports it. History and quarterly detail are in the app.
- Medical services revenue$5.9B
- Other operating revenue$11.2M
Leadership changes
From agilon health, inc.'s own filings, the day they're filed.
- Jeff Schwaneke · Chief Financial Officer · appointmenteff. 2024-07-01
- Benjamin Kornitzer · chief medical officer · departureeff. 2024-03-01
- Priscilla Kasenchak · Chief Accounting Officer · departureeff. 2023-08-11
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about agilon health, inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.